Effectiveness of Botulinum Toxin Injection in the Tennis Elbow Treatment
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Feb 20, 2007
Trial Information
Current as of August 25, 2025
Completed
Keywords
ClinConnect Summary
* Principal Objective : The first aim of the study is to value the effectiveness of botulinum toxin injection in the treatment of tennis elbow unrelieved by usual medical care performed during 6 months..
* Secondary Objective : The second aim of this study is to document the tennis elbow history by a one year following after initial injection
* Study design : It is a double blind randomized controlled trial. Principal criteria of assessment is Pain intensity three months after injection.
* Inclusion criteria : tennis elbow during more than 6 months ; signature of consent
* Exclusion criteri...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Tennis elbow during more than 6 months
- • Signature of consent
- Exclusion Criteria:
- • Less than 18 years old
- • Osteoarthritis elbow
- • Referred cervical pain
- • Fibromyalgia
- • Pregnancy
- • Myasthenia
- • Polymyositis
- • SLA
- • Anticoagulant treatment
- • Aminosides
- • Diabetes
- • Alcoholism
- • Previous botulinum toxin A injections
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux Cedex, , France
Patients applied
Trial Officials
Mathieu DE SEZE, MD
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials